- Tivic Health Systems, Inc. (TIVC, Financial) to announce Q1 2025 financial results via conference call and webcast.
- The results will be shared on May 15, 2025, at 1:30 PM PT / 4:30 PM ET.
- Tivic Health is advancing its bioelectronic and biopharma programs with FDA designations for its lead candidate, Entolimod™.
Tivic Health Systems, Inc. (TIVC), a therapeutics company focusing on the immune and autonomic nervous systems, has announced its first quarter financial results for 2025 will be disclosed on May 15th through a pre-recorded conference call and webcast. The event is scheduled for 1:30 PM PT / 4:30 PM ET. Investors can dial in toll-free at 1-877-407-0779, internationally at 1-201-389-0914, using the conference ID 13753498, or access the webcast through the provided link.
Driven by innovative bioelectronic solutions, Tivic Health is working on non-invasive medical devices that aim to enhance the efficacy of the autonomous nervous system treatments. The company’s lead product candidate, Entolimod™, currently in late-stage studies for acute radiation syndrome (ARS), has received Fast Track and Orphan Drug designation from the FDA. Tivic is also preparing an investigational new drug application and a phase 2 clinical study for treating neutropenia with Entolimod™.
Tivic Health’s existing product line includes ClearUP®, an FDA-approved device available over the counter, targeting sinus pain and pressure, and is distributed through online and commercial retailers.
For further details and updates regarding Tivic Health’s initiatives and developments in their therapeutics programs, interested parties are encouraged to visit their official website.
